DE69102465D1 - Stabilisierte Gonadotropin enthaltende Zubereitungen. - Google Patents

Stabilisierte Gonadotropin enthaltende Zubereitungen.

Info

Publication number
DE69102465D1
DE69102465D1 DE69102465T DE69102465T DE69102465D1 DE 69102465 D1 DE69102465 D1 DE 69102465D1 DE 69102465 T DE69102465 T DE 69102465T DE 69102465 T DE69102465 T DE 69102465T DE 69102465 D1 DE69102465 D1 DE 69102465D1
Authority
DE
Germany
Prior art keywords
preparations
lyophilized
dicarboxylic acid
disclosed
acid salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69102465T
Other languages
English (en)
Other versions
DE69102465T2 (de
Inventor
Andreas Leo Johannes De Meere
Marinus Arie De Ruiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of DE69102465D1 publication Critical patent/DE69102465D1/de
Publication of DE69102465T2 publication Critical patent/DE69102465T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69102465T 1990-03-20 1991-03-06 Stabilisierte Gonadotropin enthaltende Zubereitungen. Expired - Lifetime DE69102465T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90200665 1990-03-20

Publications (2)

Publication Number Publication Date
DE69102465D1 true DE69102465D1 (de) 1994-07-21
DE69102465T2 DE69102465T2 (de) 1995-03-02

Family

ID=8204967

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69102465T Expired - Lifetime DE69102465T2 (de) 1990-03-20 1991-03-06 Stabilisierte Gonadotropin enthaltende Zubereitungen.

Country Status (16)

Country Link
EP (1) EP0448146B1 (de)
JP (1) JP3031570B2 (de)
KR (1) KR100221123B1 (de)
AT (1) ATE107172T1 (de)
AU (1) AU631730B2 (de)
CA (1) CA2037884C (de)
DE (1) DE69102465T2 (de)
DK (1) DK0448146T3 (de)
ES (1) ES2057731T3 (de)
FI (1) FI101194B (de)
HK (1) HK1002494A1 (de)
ID (1) ID905B (de)
IE (1) IE64738B1 (de)
NZ (1) NZ237458A (de)
PT (1) PT97074B (de)
ZA (1) ZA911659B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
NZ265956A (en) * 1993-04-28 1996-09-25 Akzo Nobel Nv Lyospheres containing gonadotropin and compositions thereof
JP4165878B2 (ja) * 1993-06-03 2008-10-15 株式会社林原生物化学研究所 トレハロース遊離酵素とその製造方法並びに用途
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
KR100377967B1 (ko) 1995-03-21 2003-06-12 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Hcg액상조성물
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
AU776823B2 (en) * 1998-07-23 2004-09-23 Ares Trading S.A. FSH and FSH variant formulations, products and methods
US7112341B1 (en) 1999-04-13 2006-09-26 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
US7473681B2 (en) 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
EP1356809A4 (de) * 2000-12-28 2008-05-14 Takeda Pharmaceutical Retardzubereitungen
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
PT1610822E (pt) 2003-04-02 2011-01-05 Ares Trading Sa Formulações farmacêuticas líquidas ou liofilizadas de fsh e/ou lh em conjunto com o surfactante não iónico poloxâmero 188 e um agente bacteriostático
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US7740884B2 (en) * 2003-06-20 2010-06-22 Ares Trading S.A. Freeze-dried FSH/LH formulations
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
RU2418633C2 (ru) 2004-04-08 2011-05-20 Байоматрика, Инк. Объединение процессов хранения образцов и управление образцами в медико-биологических науках
JP2009526856A (ja) * 2006-02-15 2009-07-23 イムクローン・リミテッド・ライアビリティ・カンパニー 抗体製剤
DK2219607T3 (da) * 2007-11-01 2013-06-17 Merck Serono Sa Flydende LH-formuleringer
CN101269215B (zh) * 2008-05-15 2011-03-23 上海天伟生物制药有限公司 一种糖蛋白激素组合物
US8519125B2 (en) 2009-05-11 2013-08-27 Biomatrica, Inc. Compositions and methods for biological sample storage
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2635297B1 (de) 2010-11-05 2019-02-27 Baxalta GmbH Neue variante des antihämophilen faktors viii mit erhöhter spezifischer aktivität
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
WO2013063516A1 (en) 2011-10-28 2013-05-02 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
MY171140A (en) 2012-01-27 2019-09-27 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2934572A4 (de) 2012-12-20 2016-11-23 Biomatrica Inc Formulierungen und verfahren zur stabilisierung von pcr-reagenzien
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3154338B1 (de) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilisierung von thrombozyten bei umgebungstemperatur
EP4242628A3 (de) 2015-12-08 2023-11-08 Biomatrica, INC. Verringerung der erythrozytensedimentationsrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932943A (en) * 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
IT1057895B (it) * 1975-02-17 1982-03-30 Serono Lab Gonadotropina corionica umana parzialmente desalinizzata per indurre l'ouvulazione
EP0124018B1 (de) * 1983-04-28 1987-11-25 Armour Pharmaceutical Company Pharmazeutische Zubereitung mit Gehalt an gereinigtem Fibrinonectin
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration

Also Published As

Publication number Publication date
FI101194B1 (fi) 1998-05-15
ID905B (id) 1996-09-10
NZ237458A (en) 1992-02-25
HK1002494A1 (en) 1998-08-28
KR100221123B1 (ko) 1999-09-15
DE69102465T2 (de) 1995-03-02
JP3031570B2 (ja) 2000-04-10
IE64738B1 (en) 1995-09-06
KR910016340A (ko) 1991-11-05
DK0448146T3 (da) 1994-10-24
AU631730B2 (en) 1992-12-03
PT97074A (pt) 1991-10-31
FI101194B (fi) 1998-05-15
CA2037884C (en) 2003-10-21
ATE107172T1 (de) 1994-07-15
EP0448146B1 (de) 1994-06-15
ZA911659B (en) 1991-12-24
ES2057731T3 (es) 1994-10-16
AU7362391A (en) 1991-09-26
CA2037884A1 (en) 1991-09-21
IE910732A1 (en) 1991-09-25
JPH04217630A (ja) 1992-08-07
FI911309A (fi) 1991-09-21
FI911309A0 (fi) 1991-03-18
EP0448146A1 (de) 1991-09-25
PT97074B (pt) 1998-10-30

Similar Documents

Publication Publication Date Title
ATE107172T1 (de) Stabilisierte gonadotropin enthaltende zubereitungen.
HUP9800056A2 (hu) Gonadotropint tartalmazó folyékony készítmények
EP0355460A3 (de) Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
CA2125855A1 (en) A stabilized pharmaceutical formulation comprising growth hormone and histidine
RU98100930A (ru) Жидкие композиции, содержащие гонадотропин
DE69230672T2 (de) Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält
KR970706841A (ko) 성장호르몬 및 루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and leucine)
US5384132A (en) Stabilized gonadotropin containing preparations
MX9302509A (es) Composiciones de polipeptidos estables en almacenamiento y metodo para su preparacion.
US5270057A (en) Stabilized gonadotropin containing preparations
EP0294667A3 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives
EP0294668A3 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives
DE59008754D1 (de) Verfahren zur Herstellung von granuliertem Natriumacetat-Trihydrat.
DK661888A (da) Biologisk aktive molekyler

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AKZO NOBEL N.V., ARNHEIM/ARNHEM, NL

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: N.V. ORGANON, OSS, NL